Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugs

doi:10.5501/wjv.v14.i2.102673

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-2) series.

Item

Count

PDF

HTML

Tables (1-2)

Sum=0

Jun 25, 2025 (publication date) through Jun 23, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Virol. Jun 25, 2025; 14(2): 102673
Published online Jun 25, 2025. doi: 10.5501/wjv.v14.i2.102673

Table 1 Current global society recommendations for hepatitis delta virus treatment

Society	Therapy	Length of therapy
AASLD	Peg-IFN α	12 months
APASL	Peg-IFN α	12-18 months
EASL	Peg-IFN α for 48 weeks (finite therapy)
	Or Bulevirtide 2 mg daily (long term therapy)
	Or Peg-IFN α + Bulevirtide

AASLD: American Association for the Study of Liver Disease; APASL: Asia-Pacific Association for Study of Liver; EASL: European Association for the Study of the Liver; Peg-IFN: Pegylated interferon.

Citation: Park J, Sayed A, Nasir SA, Lim JK. Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugs. World J Virol 2025; 14(2): 102673
URL: https://www.wjgnet.com/2220-3249/full/v14/i2/102673.htm
DOI: https://dx.doi.org/10.5501/wjv.v14.i2.102673